Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Commentary|Articles|June 5, 2026
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
Author(s)Ashling Wahner
Fact checked by: Chris Ryan, Tracy Ann Politowicz
Breast cancer data from ASCO 2026 confirm the clinical benefits of several investigational treatment approaches across disease subtypes.
Advertisement
Advertisement
Throughout the
Related to this article
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Read a refresh of breast cancer FDA news from June 2026, including several practice-changing approvals and the granting of priority review to a SERD.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Advertisement
Advertisement